DDInter623 DDInter1938
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Voacamine
Voacamine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is downregulated by {v} (Compound) Vincristine
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Voacamine
Voacamine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Voacamine (Compound) and Voacamine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds NQO1 (Gene) and NQO1 (Gene) is downregulated by Vincristine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Voacamine (Compound) and Voacamine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)